Ir para o conteúdo principal

NextCure (NASDAQ: NXTC) — Perfil da empresa, notícias e dados financeiros

Logo de NextCure 
NXTC NextCure 
NextCure  primary media
Perfil da empresa

NextCure 

NextCure (NASDAQ:NXTC) is a biotechnology company focused on discovering and developing novel immunotherapies for cancer and other immune-related diseases. By leveraging its proprietary FIND-IO™ platform, NextCure aims to identify and advance therapeutic proteins and peptides that harness the body's immune system to fight disease effectively. The company's pipeline of projects includes several promising candidates in different stages of development, aimed at addressing unmet medical needs across various oncological indications. With a commitment to innovation and patient welfare, NextCure's objective is to push the boundaries of scientific research to provide new, effective treatments that improve patient outcomes and quality of life.

Resumo

Public USParticipação acionária
2015Ano de fundação
82Funcionários
Maryland, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de NextCure 

  • NC318, an immunomedicine targeting Siglec-15, aimed at enhancing immune system's ability to fight cancer.
  • NC410, a novel immune modulator designed to restore immune recognition and kill cancer cells.
  • NC762, a monoclonal antibody that targets B7-H4, potentially inhibiting tumor growth.
  • Collaboration with Yale University to identify novel cancer targets, leveraging NextCure's FIND-IO platform.

equipe executiva do NextCure 

  • Michael S. RichmanCo-Founder, CEO, President & Director
  • Timothy MayerChief Operating Officer
  • Udayan GuhaChief Medical Officer
  • Lieping ChenCo-Founder & Chairman of Scientific Advisory Board
  • Steven P. CobournChief Financial Officer
  • Kevin G. ShawSenior VP & General Counsel
  • Sourav KunduSenior Vice President of Development & Manufacturing
  • Sebastien MalovesteSenior Vice President of Business Development

Principais indicadores financeiros

Resultados divulgados pela NextCure , em USD.

Cap. de mercado
26,2 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-8.7
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da NextCure 
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-57,6 mi-55,8 mi
0-59,7 mi-55,7 mi
0-67,6 mi-62,7 mi
0-75,9 mi-69,4 mi